Format

Send to

Choose Destination
Euro Surveill. 2018 Feb;23(5). doi: 10.2807/1560-7917.ES.2018.23.5.18-00035.

Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, January 2018.

Author information

1
University of British Columbia, Vancouver, Canada.
2
British Columbia Centre for Disease Control, Vancouver, Canada.
3
Centre Hospitalier Universitaire de Québec, Québec, Canada.
4
Laval University, Quebec, Canada.
5
Institut National de Santé Publique du Québec, Québec, Canada.
6
University of Calgary, Calgary, Canada.
7
Public Health Ontario, Toronto, Canada.
8
University of Alberta, Edmonton, Canada.
9
Alberta Provincial Laboratory, Edmonton, Canada.
10
University of Toronto, Toronto, Canada.
11
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Abstract

Using a test-negative design, we assessed interim vaccine effectiveness (VE) for the 2017/18 epidemic of co-circulating influenza A(H3N2) and B(Yamagata) viruses. Adjusted VE for influenza A(H3N2), driven by a predominant subgroup of clade 3C.2a viruses with T131K + R142K + R261Q substitutions, was low at 17% (95% confidence interval (CI): -14 to 40). Adjusted VE for influenza B was higher at 55% (95% CI: 38 to 68) despite prominent use of trivalent vaccine containing lineage-mismatched influenza B(Victoria) antigen, suggesting cross-lineage protection.

KEYWORDS:

Influenza; genomics; influenza virus; mid-season; vaccine effectiveness; vaccine-preventable diseases; vaccines and immunisation

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center